Detalhe da pesquisa
1.
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Lancet Oncol
; 25(3): 317-325, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342115
2.
Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Int J Cancer
; 154(4): 701-711, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37831416
3.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882206
4.
Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens.
Breast Cancer Res Treat
; 205(1): 29-37, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38261228
5.
CDK4/6 inhibitors: The Devil is in the Detail.
Curr Oncol Rep
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713311
6.
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
Future Oncol
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38536033
7.
Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
Future Oncol
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517416
8.
Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer: the association of social determinants of health and neighborhood socioeconomic disadvantage.
Support Care Cancer
; 32(4): 224, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38472437
9.
The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancer.
Cancer
; 129(19): 3034-3043, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243943
10.
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer.
Oncologist
; 28(11): e1123-e1126, 2023 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725049
11.
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Oncologist
; 28(10): 866-874, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37487056
12.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944848
13.
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
BMC Cancer
; 23(1): 606, 2023 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37391697
14.
Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary.
Future Oncol
; 19(7): 489-498, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892508
15.
"I was never one of those people who just jumped right in for me": patient perspectives on self-advocacy training for women with advanced cancer.
Support Care Cancer
; 31(1): 96, 2023 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36598659
16.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
N Engl J Med
; 380(25): 2395-2405, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157962
17.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112166
18.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 195(2): 127-139, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545724
19.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230585
20.
The importance of accessory protein variants in the pathogenicity of SARS-CoV-2.
Arch Biochem Biophys
; 717: 109124, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35085577